Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
37 participants
OBSERVATIONAL
2024-06-05
2024-11-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine
NCT04825678
Registry for Migraine - Clinical Core
NCT04603976
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
NCT03828539
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
NCT04252742
Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment
NCT04674020
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adult migraine patients
adult migraine patients across the 4 Gulf Countries (UAE, Qatar, Oman and Kuwait)
erenumab
This was an observational study, there was no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients were directed through a link to the full survey.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
erenumab
This was an observational study, there was no treatment allocation. After fulfilling the inclusion criteria and signing the informed consent, patients were directed through a link to the full survey.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
* Ability to receive 3 monthly doses of erenumab.
* Age more than 18 years
* Males and Females
* Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
* Agreed to be included in the study and signed informed consent
Exclusion Criteria
* Age at onset of Migraine more than 50 years
* Any contraindications to the start of erenumab as per label
* Refusal to sign informed consent
* Inability to participate or restricted access to the online survey
* Enrolled in an interventional migraine-related study at the time of the study enrollement
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Related Links
Access external resources that provide additional context or updates about the study.
Link to study results
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAMG334AAE02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.